ACADIA Pharmaceuticals Soars on Early Approval of Parkinson’s Treatment

Michael Teague |

ACADIA Pharmaceuticals (ACAD) was up 55.60 percent on Thursday, with shares trading as for as much as $12.40, after Wednesday’s closing price of $7.97.

ACADIA makes drugs that treat neurological and central nervous system-related disorders. Currently, the company is developing pimavanserin for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia.



The $934.86 million market-cap company’s performance was sparked by the announcement that its pimavanserin Parkinson’s disease psychosis treatment qualifies for the filing of a New Drug Application (NDA) without requiring the customary final-phase trial that was scheduled to commence later in the month.

For as many as 40 percent of those with advanced-stage Parkinson’s disease, psychosis is a commonly experienced complication, often in the form of visual hallucinations. Furthermore, Parkinson’s-related psychosis can be induced by more or less all drugs used to treat the disease.

In a statement released earlier in the day, the company said that the Food and Drug Administration “has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing.”

ACADIA will now have to finish up testing and studies, and plans to submit the NDA request by the end of 2014.

Company CEO Dr. Uli Hacksell was quoted in the company’s statement as being happy with the FDA’s decision, saying that it “will reduce substantially both the time and cost of our PDP development program.”

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ACAD ACADIA Pharmaceuticals Inc. 30.43 0.34 1.13 1,204,332 Trade
WAG26 Walgreens Boots Alliance Inc 2.125% Eur Nt Due 202 n/a n/a n/a 0 Trade

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…